Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4WJX3)

• Drug Name: 3-methoxy-N-(4-methylthiazol-2-yl)benzamide Drug Info
• Synonyms: CHEMBL211740; 477516-34-0; 3-methoxy-N-(4-methyl-1,3-thiazol-2-yl)benzamide; SMR000155061; AC1MAGB1; 3-methoxy-N-(4-methylthiazol-2-yl)benzamide; Oprea1_281072; Oprea1_273858; MLS000569675; CTK4J0236; cid_2679292; DTXSID80369021; MolPort-000-631-036; CHEBI:114888; HMS2341M09; ZINC3562014; BDBM50186332; AKOS001313290; MCULE-7375167923; KB-288021; BENZAMIDE, 3-METHOXY-N-(4-METHYL-2-THIAZOLYL)-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 2679292
  ChEBI ID: CHEBI:114888
  CAS Number: CAS 477516-34-0
  TTD Drug ID: DM4WJX3

Molecule-Related Drug Atlas

Drug(s) Targeting LOX-5 messenger RNA (ALOX5 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TEBUFELONE	DMMUE8P	Pain	MG30-MG3Z	Discontinued in Phase 2	[3]
ZD-2138	DMVFCX7	Asthma	CA23	Discontinued in Phase 2	[4]
BW A4C	DMNUMDG	Arthritis	FA20	Terminated	[5]
Kaempferol	DMHEMUB	Discovery agent	N.A.	Investigative	[6]
2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl	DMWNJ84	Discovery agent	N.A.	Investigative	[7]
METHYLHONOKIOL	DM9YE6K	Discovery agent	N.A.	Investigative	[7]
HONOKIOL	DMJWT3X	Discovery agent	N.A.	Investigative	[7]
PUUPEHEDIONE	DMF28IU	Discovery agent	N.A.	Investigative	[8]
PUUPEHENONE	DMF3BCK	Discovery agent	N.A.	Investigative	[8]
Isojaspic acid	DMHTBDN	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Metabotropic glutamate receptor 5 (mGluR5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Afq056	DMMHSLC	Fragile X syndrome	LD55	Phase 2/3	[9]
ADX-48621	DM6GTMD	Parkinson disease	8A00.0	Phase 2/3	[10]
RG-7090	DMX8JYN	Fragile X syndrome	LD55	Phase 2	[11]
STX-107	DMLNKX7	Autism spectrum disorder	6A02	Phase 2	[12]
ADX10059	DMGVKHQ	Anxiety disorder	6B00-6B0Z	Phase 2	[13]
McN3377	DMTCADJ	Fragile X syndrome	LD55	Phase 1/2	[14]
MK-3328	DMW2O5D	Alzheimer disease	8A20	Phase 1	[15]
[3H]fenobam	DMBOXA1	Allodynia	MB40.1	Phase 1	[16]
RG7342	DMIW5NG	Schizophrenia	6A20	Phase 1	[17]
Tetra-hydro-oxazolopyridine derivative 2	DMP65Z4	N. A.	N. A.	Patented	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
LOX-5 messenger RNA (ALOX5 mRNA)	TTSJ6Q4	LOX5_HUMAN	Inhibitor	[2]
Metabotropic glutamate receptor 5 (mGluR5)	TTHS256	GRM5_HUMAN	Inhibitor	[1]

References

• [1] Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5.
• [2] Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
• [3] New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflam... J Med Chem. 1998 Aug 27;41(18):3515-29.
• [4] Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines. Bioorg Med Chem. 2010 Jun 1;18(11):3910-24.
• [5] Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid. J Med Chem. 2008 Sep 11;51(17):5449-53.
• [6] Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62.
• [7] Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
• [8] Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63.
• [9] Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos. 2013 Sep;41(9):1626-41.
• [10] Pipeline of Addex Pharma. Addex Pharma. 2009.
• [11] The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014; 231(6): 1237-1250.
• [12] Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. J Can Acad Child Adolesc Psychiatry. 2014 February; 23(1):20-30.
• [13] A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and... Gut. 2009 Sep;58(9):1192-9.
• [14] Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293).
• [16] Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agon... J Pharmacol Exp Ther. 2005 Nov;315(2):711-21.
• [17] Clinical pipeline report, company report or official report of Roche.
• [18] mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.